ESC 2025 congress intelligence

What should Alnylam do with the post-HELIOS-B ATTR-CM narrative?

Executive answer

ESC 2025 gives Alnylam permission to move from “novel RNAi option” to “first-line treatment architecture.”

The strongest narrative shift is not simply that AMVUTTRA has more data. It is that the ATTR-CM conversation is now about treatment class selection, durability, outcomes beyond survival, and whether TTR knockdown should be introduced earlier.

ATTR signals in dataset 1,660
ATTR signals in 2025 539
ESC 2025 ATTR signals 251
Recommended move

Test a sharper first-line narrative

Position AMVUTTRA as the only approved RNAi treatment addressing ATTR-CM at its source, with durable benefit across mortality/CV events, function, QoL and biomarkers.

HELIOS-B signal

The data story executives need to see first

ESC 2025 + label-confirmed endpoints
Primary endpoint All-cause mortality + recurrent CV events

During double-blind treatment up to 36 months, AMVUTTRA reduced risk by 28% overall and 33% in monotherapy patients.

ESC 2025 OLE update Benefit through up to 48 months

New analyses reported 37% risk reduction for all-cause mortality or first CV event overall and 42% in monotherapy.

Clinical texture QoL, biomarkers and function

KCCQ-OS, NT-proBNP, 6MWT and days lost to death/hospitalization give Alnylam a broader outcomes narrative.

Strategic implication Earlier, durable knockdown

The story can shift from “add-on option” toward a first-line treatment consideration anchored in TTR knockdown.

Competitor readout

What Pfizer and BridgeBio are likely to say next

Narrative-risk view
Pfizer Tafamidis / Vyndaqel / Vyndamax

Likely defense

Reinforce stabilizer familiarity, real-world experience, long-standing physician comfort, and a simple “start with stabilization” treatment pattern.

What HELIOS-B threatens

AMVUTTRA can challenge tafamidis by tying rapid TTR knockdown to clinical outcomes, monotherapy benefit, and a mechanism that acts upstream of amyloid formation.

Alnylam counter-message

“In a progressive disease, treatment choice should not stop at stabilization; durable TTR knockdown offers a source-directed RNAi approach with outcomes that matter.”

BridgeBio / Bayer Acoramidis / Attruby / Beyonttra

Likely offense

Lead with “near-complete TTR stabilization,” early benefit, cardiovascular mortality reduction, NT-proBNP stabilization, 6MWT, KCCQ and oral administration.

What this means for Alnylam

Acoramidis will try to own “best stabilizer” and may pull the market into a stabilizer-versus-stabilizer comparison unless Alnylam reframes the class question.

Alnylam counter-message

“The future question is not which stabilizer is stronger; it is which therapeutic approach best changes the disease trajectory for the right patient.”

Market narrative Class selection is the new battlefield
  • Stabilizers will emphasize oral simplicity and TTR stabilization.
  • RNAi should emphasize source-directed knockdown and durable outcomes.
  • KOLs will ask sequencing and combination questions.
  • Field teams will need crisp language for first-line eligibility.
Narrative strategy

Recommended Alnylam positioning architecture

Ready for synthetic validation
Core story

From “RNAi innovation” to “source-directed first-line ATTR-CM care.”

Anchor the story in TTR knockdown, sustained clinical benefit, and the patient-relevant outcome set: mortality, CV events, function, QoL and biomarkers.

Audience-specific phrasing

For cardiologists

“Earlier TTR knockdown may help slow the clinical trajectory before irreversible progression dominates decision-making.”

Competitive reframing

Against stabilizer narratives

Move the conversation away from convenience-only comparisons and toward mechanism, durability, progression, and which patient profiles need more than stabilization.

Document impact

Assets that should be refreshed after ESC 2025

Scientific Communication Platform
Lexicon Analysis
SWOT
Situational Analysis
Field FAQ
Synthetic Insight Studio

Turn the narrative into a testable executive decision

Recommended next action
Rapid synthetic KOL reaction

Test the “source-directed first-line” narrative

Ask synthetic cardiology KOLs whether HELIOS-B supports earlier AMVUTTRA use, where tafamidis remains preferred, and how acoramidis changes the treatment-choice frame.

12 KOL archetypes US / EU / Japan 48-hour readout
Simulated advisory board

Sequence, switch or combine?

Explore whether KOLs think in mechanism classes, patient phenotypes, endpoints, convenience, safety, or payer access when selecting among tafamidis, acoramidis and AMVUTTRA.

Question bank
  • Does HELIOS-B justify a first-line RNAi claim in your mental model?
  • Which endpoint carries the most persuasion: mortality, CV events, KCCQ, NT-proBNP or 6MWT?
  • Where does acoramidis create the sharpest competitive pressure?
  • What wording sounds credible without overreaching?
Evidence chain

Every recommendation stays attached to source context

Glass-box provenance
Evidence event Key signal Recommended action Confidence
HELIOS-B ESC 2025 OLE Durable benefit through up to 48 months; mortality/CV event, QoL and biomarker story Refresh SCP and run KOL reaction High
Acoramidis ATTRibute-CM OLE CVM reduction, near-complete stabilization and early sustained benefit narrative Update SWOT and competitor objection handling High
ESC 2025 ATTR-CM sessions Treatment selection, stabilizers vs silencers, AI referral pathways, outcomes beyond survival Refresh lexicon and field FAQ Medium-high